Founded in 2016, SINGMED is committed to the design, R&D, and manufacturing of complex drug delivery devices, as well as the development of drug-device combination products. It is also committed to empowering the clinical efficacy of drug delivery, providing Chinese physicians and patients with more high-quality and affordable treatment options.
- Founded in Oct 2016
- Developed first-generation single-dose capsule DPI platform.
- Developed a new single-dose capsule DPI platform.
- Developed multi-dose blister DPI platform and soft mist inhaler platform.
- Developed innovative Dual-Power aqueous nasal spray device
- More portfolio with technical development
- Drug-device combination programs using Singmed’s capsule DPI and SMI platforms completed bioequivalence evaluation.
- A multi-dose blister DPI combination program completed NMPA bioequivalence evaluation.
- More inhalation and nasal device portfolio
- Active Primary Packaging
- Bought 26,700 ㎡ land for R&D and manufacturing centre in Changshu.
- Open Shanghai sales office
- Changshu Singmed advanced drug delivery device R&D and manufacturing base officially commenced operations
